For the millions of adults and children managing ADHD with medications that carry cardiovascular risks, abuse potential, or inadequate symptom control, a credible non-stimulant alternative would represent a meaningful clinical advance. A new meta-analysis of randomized controlled trials quantifies, for the first time in pooled form, exactly how well centanafadine performs against placebo — and how safely.
Centanafadine is a triple monoamine reuptake inhibitor (TMRI) that simultaneously targets norepinephrine, dopamine, and serotonin transporters, a mechanism distinct from both classic stimulants (which primarily act on dopamine and norepinephrine via release or reuptake blockade) and approved non-stimulants like atomoxetine (selective norepinephrine reuptake inhibitor) or guanfacine (alpha-2 agonist). The systematic review, drawing on placebo-controlled RCTs identified across PubMed, Embase, Scopus, and ClinicalTrials.gov, pooled primary outcomes using standardized mean differences (Hedges' g) and applied random-effects meta-analysis with Hartung-Knapp adjustment — a methodologically conservative approach that tends to widen confidence intervals and reduce false precision. Secondary outcomes included clinician-rated global severity via the CGI-S scale, and safety data captured overall adverse event incidence.
Contextually, centanafadine's TMRI profile is intriguing because serotonergic co-modulation may confer mood-stabilizing benefits relevant to the high ADHD-anxiety comorbidity burden, though it also raises questions about differentiation from antidepressants. The existing ADHD pharmacotherapy pipeline is thin for non-stimulants; viloxazine extended-release received FDA approval in 2021, and centanafadine has been in Phase III development. A limitation worth flagging: the excerpt does not confirm the number of trials ultimately included, and the pooled sample size will determine statistical power and generalizability. Observational durability and long-term cardiovascular or metabolic safety — historically underexplored in ADHD drug development — remain open questions. Taken at face value, a well-conducted meta-analysis of RCTs represents the strongest available evidence tier, making this analysis potentially informative for prescribers navigating an underserved non-stimulant space.